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Abstract
Diabetes is a common chronic illness that affects millions of people in the United States.
Poorly controlled diabetes can lead to health complications that impact quality of life,
increase healthcare costs, and create a negative impact on communities. Pharmacological
management of diabetes was identified by stakeholders as a gap in practice at a clinic in
the southeastern United States. The purpose of this project was to develop staff education
based on American Diabetes Association (ADA) and American Association of Clinical
Endocrinologists (AACE) standards of care, deliver education to primary care nurse
practitioners (NPs), and evaluate their learning and confidence levels. The primary
framework for this project was the chronic care model. An expert panel, including 2
board-certified endocrinologists and a registered nurse diabetic educator, reviewed the
educational materials and agreed the presentation was clinically appropriate for the
intended audience and the content was current and accurate. Seven NPs participated in
the preassessment survey and education program, and six NPs completed the
postassessment survey. Preassessment and postassessment surveys asked 13 questions
rated on a Likert-type scale from 5 (very comfortable) to 1 (very uncomfortable).
Participant responses showed an increase to comfortable and very comfortable on 12
survey items. Posteducation survey items showed that 100% of participants were very
comfortable in adjusting premixed insulin, treatment guidelines, and classes of
medication and their effectiveness. Implications for positive social change related to this
doctoral project include increased staff knowledge, improved patient outcomes,
decreased healthcare costs, and a decrease in the community burden of diabetes.
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Section 1: Nature of the Project
Diabetes is an increasingly common chronic illness. According to the Centers for
Disease Control and Prevention (CDC, 2016), more than 30.3 million people in the
United States are currently affected by this chronic illness. In the state of Georgia, 10.7%
of the population currently suffer from diabetes (CDC, 2016). Poorly controlled diabetes
can lead to diabetic complications. Patients with diabetes account for more than 30% of
all noncritical hospitalized patients. The average age of those admitted was 65 years old
(Ables et al., 2016). The costs of diabetes management, complications, and
hospitalizations are currently more than 245 billion dollars. The estimated per-person cost
for diabetes care and associated complications can reach more than $10,000 over 8 years.
One fourth of that amount can be spent within the first year following diagnosis (Rosella
et al., 2016). However, many complications and hospitalizations can be decreased or
prevented starting at the outpatient primary care level.
Current literature shows that blood glucose control is a critical part of obtaining
and maintaining long-term health (American Association of Diabetic Educators, 2017).
Prevention of hyperglycemia in the non-critically ill patient helps to decrease infection,
complication, morbidity, mortality, and hospital admission (Corsino et al., 2017).
Metabolic and hormonal changes experienced by patients living with diabetes often lead
to hyperglycemia, which in turn can lead to immune dysfunction; hemodynamic effects,
such as dehydration and electrolyte loss; and tissues effects, including inflammation,
oxidative stress, and endothelial dysfunction (Umiperrez & Lansang, 2016).
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The gap in practice addressed by this doctoral project was the lack of confidence
in knowledge of nurse practitioners (NPs) to treat their patients with diabetes. This staff
education program was created with the intention of increasing provider knowledge in
pharmacological management of diabetic patients using evidence-based practice. This
project can lead to positive social change by helping providers at the project site increase
their knowledge and confidence. In turn these providers can use this knowledge to help
improve patients’ quality of life and long-term health and decrease complications and
overall diabetes-related healthcare costs (Spruce, 2015)
Problem Statement
People with diabetes are three times more likely to be hospitalized than people
without diabetes. Uncontrolled and recurrent hyperglycemia is a common condition but is
often preventable with appropriate management (Umiperrez & Pasquel, 2017). The
healthcare effectiveness data and information set (HEDIS) is a method adopted by
Medicare and other private payers to determine clinicians’ performance levels. Clinicians
can be held accountable and receive a decrease in compensation for a failure to meet
HEDIS measures. HEDIS measures for diabetes are (a) a hemoglobin (A1C) less than
8%, (b) low-density lipoprotein cholesterol (LDL-C) of less than 100 mg/dL, (c) blood
pressure (BP) less than 140/90 mmHg, and (d) aspirin therapy in the presence of ischemic
vascular disease (McCoy et al., 2017). Failure to meet these measures can have dire
consequences on the patients and the providers. Consequences to the patients include
poor health outcomes and diabetic complications, such as nephropathy, loss of income
and financial burden. Primary care providers like those associated with the project site
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can experience negative scoring that follows their reimbursement rates under CMS for
the next year. The project site has experienced a decrease in revenue due to the adjusted
reimbursement percentage (McCoy et al., 2017). Administrators at the project site stated
to me that they have not been meeting all their HEDIS measures for diabetes. Many
patients at the project site are not meeting their A1C goals. There has been an increase in
patients being admitted to the hospital with diabetic-related complications. Some factors,
such as patient compliance and ability to afford their medications, are beyond provider
control. Provider knowledge in pharmacological management of diabetes and confidence
in that knowledge was the component I sought to address in this DNP project.
The small private practice in which the project took place is unique in nature. The
practice provides all aspects of primary care and more to homebound patients.
Homebound criteria are defined by and set forth by Medicare (Cigna Government
Services, 2017). Each patient has a different level of physical, mental, emotional, and
financial ability to see specialists, such as endocrinologists. All project site patients are
managed by NPs. Several of the providers expressed limited knowledge in the
management of diabetes, including pharmacological choices and the associated
pharmacokinetics. I sought to address this important component of patient care in this
DNP project to help improve patients’ abilities to maintain safe and adequate glucose
control.
Purpose Statement
The purpose of this project was to develop staff education based on American
Diabetes Association (ADA) and American Association of Clinical Endocrinologists
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(AACE) standards of care, deliver the education to primary care NPs, and evaluate their
learning and confidence levels. I used the standards of care to create an educational
program that provided detailed information regarding diabetic pharmacology,
considerations, mechanism of actions, and a treatment algorithm. The gap in practice
addressed in this DNP project was the lack of adequate knowledge of pharmacological
management of diabetic patients by new NPs.
The practice-focused question that guided this project was: Will an educational
program presented to primary care NPs on the pharmacological management of diabetic
patient increase the nurse practitioners perceived confidence and knowledge in treating
and managing diabetic patients? According to the ADA, each person living with diabetes
requires individualized treatment plans that best fit each person’s complex needs. The
goal of this project was to develop a staff education that would help to increase the
confidence of each provider to properly select the appropriate medications for their
diabetic patients based on evidence-based practice.
Overview of the Doctoral Project
The project site where this staff education project took place is a small primary
care in-home practice in a major city in southeastern Georgia. Most of the providers are
new NPs who do not feel they have enough knowledge and experience to properly care
for and treat diabetic patients. During my tenure as a provider there, I had conversations
with several of these NPs over the years. These conversations served as a contributing
factor in creating this DNP project. To answer the practice-focused question, I provided a
30-minute program using a PowerPoint presentation through a real-time virtual platform.
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The goal of this DNP project was to increase the confidence and knowledge among NPs
in a small primary care practice who make house calls to homebound patients. The
expected outcome was that, following a short but intensive staff education program on
pharmacological management of diabetic patients, NPs would report a perceived sense of
increased confidence and knowledge to make timely and appropriate decisions on
medication management while partnering with their patients. The virtual platform was
selected as a presentation method due to continued concerns regarding the COVID-19
global pandemic. The project site continues to provide telehealth services and is
conducting all meetings virtually. The content of the staff education program provided
current treatment guidelines, pharmacokinetics, considerations, and contraindications to
medication therapy and management in the diabetic patient. A pretest survey and a
posttest survey were given to assess participants’ perceived knowledge and confidence in
pharmacological management of diabetic patients. A 13-question Likert scale survey I
created was used to complete the assessment of the participants both before and after the
staff education intervention. The survey questions were rated on a scale from 0–10 to
assess the NPs’ level of comfort both before the presentation and after. Descriptive
statistics were used to analyze the data from the pretest survey and posttest survey.
The literature review on diabetes was completed using the following key search
terms: diabetes, nurse practitioner, new provider, confidence, diabetes management,
insulin, basal, prandial, bolus, glycemic control, hyperglycemia, hypoglycemia, and
outcomes. Exclusion criteria includes pediatric and gestational diabetes articles and nonEnglish articles. I used information found in databases, such as CINAHL, Medline,

6
PubMed, NIH, and Embassy. Other sources of evidence included guidelines from the
ADA and AACE. The search focused on sources written between 2014 and 2020. All
articles used were peer-reviewed and published within the past 6 years. Exceptions were
made for appropriate historical articles. Input and opinions from an expert panel
consisting of two endocrinologists and one registered nurse educator also served as an
additional source of evidence.
Significance
There are 166 endocrinologists in the state of Georgia (Elflein, 2019), which
makes referrals difficult and accompanied by long wait times. Many patients cannot and
will not go to a specialist due to an inability to afford medical transport. While working
as a provider at the project site several patients cited transportation costs to be between
300 dollars and 700 dollars each way or roundtrip. Many of these patients have
associated diabetic complications, such as chronic kidney disease, and many have been
hospitalized due to these complications. It is essential that primary care providers have
confidence in understanding how to best manage their diabetic patients.
In this practice, most of the care and pharmacological management of diabetic
patients is provided by NPs. Therefore, it is essential that these NPs feel confident and
able to provide evidence-based care that is individualized. Many providers in the primary
care setting take a one-size-fits-all approach to diabetes management (Rushforth et al.,
2016), which does not incorporate individual patient needs. In-depth training on clinical
guidelines and the pharmacokinetics of various medications will help practitioners feel
better equipped and experience increased confidence in their ability to create an
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individualized treatment plan for diabetic patients. This project aligns with DNP
Essentials I, II, III, and VIII, which address the scientific underpinnings for practice and
information systems/technology for the improvement and transformation of health care
(American Association of Colleges of Nursing, 2006).
The stakeholders for this project include all physicians, NPs, administrators, and
diabetic patients of the project site. Both physicians and nurses may benefit by increasing
knowledge on managing these complex patients. The education program supports the
positive impact of increasing provider confidence in selecting appropriate
pharmacological management for patients, thereby obtaining better patient outcomes and
satisfaction. The administrative staff may benefit by seeing an increase in reimbursement
for services due to meeting HEDIS measures and keeping patients out of the hospital.
Patients may benefit by experiencing increased quality of life, better outcomes, and fewer
complications. These benefits illustrate the potential for positive social change.
Summary
In Section 1, I provided the introduction to this DNP capstone project. The
purpose of the project was to provide evidence-based staff education to primary care NPs
on pharmacological management of patients living with diabetes. Section 1 included an
overview of the nature of the DNP project, the problem statement, purpose, practicefocused question, and significance of the project. Section 2 will include a discussion of
the chronic care model (CCM) as a framework for the DNP project, relevance of the DNP
project to nursing practice, local background, context, and my role in this project as the
DNP student.
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Section 2: Background and Context
Millions of people are affected by diabetes, a complex chronic disease. I have
focused this DNP capstone project on a staff education project to provide
pharmacological diabetic management education to a group of primary care NPs. In this
section, I discuss the concepts and models that served as frameworks for this DNP
project. In addition, I discuss the project’s relevance to nursing, the local background and
context, and my role as the DNP student. This project was important to the local primary
care practice. The NPs within the group provide over 97% of all diabetic management for
their patients. The ADA (2019) standards of care state that treatment modalities in the
management of diabetes should be timely, based on evidence, and utilize a collaborative
approach taking into consideration the patients’ prognoses, preferences, and
comorbidities. The treatment plan should be aligned with the CCM. Primary care
providers should ensure that treatment plans take into consideration socioeconomic
factors and use a team–community approach whenever possible (ADA, 2019).
The purpose of this project was to develop staff education based on ADA and
AACE standards of care, deliver the education to primary care NPs, and evaluate their
learning and confidence levels. With this project, I aimed to address an important
knowledge gap and increase NPs’ confidence in managing their patients by answering the
practice-focused question. The practice-focused question that guided this project was:
Will an educational program presented to primary care NPs on the pharmacological
management of diabetic patient increase the practitioner’s perceived confidence and
knowledge in treating and managing diabetic patients? In this section, I discuss the CCM
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as the major framework for this project. In addition, I discuss the project’s relevance to
nursing practice, local background and context, my role as the DNP student, and the role
of the project team.
Concepts, Models, and Theories
Chronic Care Model
The CCM is an evidence-based practice model designed to encourage care teams
to manage chronic illness using a variety of approaches (Baptista et al., 2016; Stellefson
et al., 2013). The CCM consists of six components that help guide providers into a
systematic approach to managing chronic conditions such as diabetes. CCM encourages
providers to use all resources to manage patients with chronic diseases such as diabetes
(Baptista et al., 2016; Stellefson et al., 2013). The six components of the CCM are
purposed to make all resources available through the organization of heath care, while
minimizing barriers to access to care. The six components include: (a) self-management
support; (b) decision support and guidance for evidence-based care implementation; (c)
delivery system design, used for coordinating care processes; (d) clinical information
systems, used to track progress and to report patient outcomes; (e) community
information systems, also used to track progress and report outcomes; and (f) community
resources and polices, which involves use of community-based resources.
This model is relative to the DNP project because it is used to address the
importance of support from healthcare organizational leaders. In this project, the
organizational leadership includes the administrator and medical director. In their support
of this project, they are promoting a culture of quality care, facilitating communication,
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and managing quality control issues (Baptista et al., 2016; Stellefson et al., 2013). The
CCM encourages partnership between the provider and the patient to identify issues, set
goals, set priorities, and develop plans of care (Baptista et al., 2016). The CCM is the
primary model of consideration for the ADA. The ADA standards of care are evidencebased guidelines for primary care providers caring for patients affected by diabetes. The
primary component of the CCM that is the focus of this project is providing training to
help create a decision support model for medical practitioners to apply evidence-based
treatment modalities for diabetic patients. In this case, the primary team members are the
patient and the provider. The PowerPoint presentation used for the training incorporated
the ADA standards of care regarding pharmacological management of latent autoimmune
diabetes in adults (LADA) and Type 2 diabetes mellitus.
The use of scientifically based clinical guidelines in decision making fosters a
treatment delivery system that promotes clinical excellence. The CCM is appropriate for
use in this project as it promotes the support of organization leaders, such as the medical
director, collaborative physicians, and administration, in identifying necessary resources
and reducing barriers to practice change that should be evidence based.
Definition of Terms
Clinical Inertia: The failure to initiate or intensify treatment when clinically
indicated (Smith, 2019).
Socioeconomic Status: A combination of income and occupation used to classify
the social standing of an individual or group.
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Certified Diabetes Care and Education Specialist (CDCES): A licensed professional

with extended knowledge in diabetes management (CBDCE.org, 2020).
HbA1C: Hemoglobin A1C blood laboratory tests provide the average blood
glucose levels over 3 months, which is the period that represents the life of the red blood
cell (ADA, 2019).
Microvascular: Involving small blood vessels, such as capillaries, includes
retinopathy, nephropathy, and neuropathy and results in organ and tissue damage
(Chawla et al., 2016).
Macrovascular: Involving large blood vessels, such as arteries and veins, includes
ischemic heart disease, peripheral vascular disease, and cerebrovascular disease. These
complications result in organ and tissue damage (Chawla et al., 2016).
Sodium Glucose Cotransporter 2 Inhibitors (SGLT-I): Oral antidiabetic
medication that decreases reabsorption of glucose by the kidneys (Hsia et al., 2017).
Dipeptidyl Peptidase 4 Inhibitors (DPP4): Oral antidiabetic medication that
inhibits dipeptidyl peptidase (DPP) on the surface of most cells. DPP4 deactivates
peptides such as GLP-1. DPP4 decreases insulin secretion associated with meals, delays
gastric emptying, and decreases postmeal glucagon (Dungan & DeSantis, 2020).
Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA): Works on GLP-1, which
is a gastrointestinal peptide that releases glucose in the setting of meals. GLP-1-RA is an
injectable antidiabetic therapy that works to stimulate insulin synthesis, delays gastric
emptying, and decreases postmeal glucagon (Dungan & DeSantis, 2020).
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Relevance to Nursing Practice
Primary care NPs are often the first line providers in the management of diabetes.
Continuing education, clinical competence, and evidence-based practice are the
cornerstones of quality patient care provided by NPs (Black et al., 2015). The ADA
(2019) promotes evidence-based treatment plans individualized to each patient. NPs who
are aware of how each medication works and of considerations for each medication are
better able to meet this goal.
Types of Diabetes
There are multiple types of diabetes. This project focused on medical
management of LADA and Type 2 diabetes. LADA and Type 2 are the two most
common forms of diabetes encountered at the project site. Type 2 diabetes is a results of
cumulative insulin resistance and hyperglycemia, which cause insulin secretion
deficiencies (ADA, 2018). Type 2 diabetes is one of the most common types of diabetes
encountered in primary care (Seidu et al., 2020). LADA is a common autoimmune
disease like Type 1 diabetes in which a patient’s pancreas stops producing adequate
insulin due to some sort of insult that damages the beta cells of the pancreas (ADA,
2018).
LADA is often mistaken for Type 2 diabetes, especially among older adults.
Because of this, my project did not focus on Type 2 diabetes alone. LADA patients are
often started on oral agents due to misperception that they have Type 2 diabetes. But oral
agents will not work for patients with LADA because LADA is an autoimmune form of
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the disease process; LADA patients require insulin and management as though they have
Type 1 diabetes (Carlsson, 2019).
Treatment Guidelines
ADA Standards of Care
ADA standards of care provide evidence-based guidelines in the treatment and
management of diabetes. The ADA Professional Practice Committee is comprised of
healthcare professionals of all types and levels. The Professional Practice Committee
completes systematic literature searches for new evidence and grade the evidence using a
rating system. The committee receives feedback during the year and generates the
standards of care (Chamberlain et al., 2016). These standards of care address (a)
diagnosis of diabetes, (b) recommendations for glycemic targets, (c) medical
management of diabetes, (d) risk management for cardiovascular disease, (e)
microvascular disease management, and (f) diabetic care in hospital (Chamberlain et al.,
2016). In this project I focused on Standard 9 regarding pharmacological approaches to
glycemic treatment (ADA, 2019). This standard addresses recommendations of initiation
of treatment.
The ADA standards of care have developed a treatment algorithm to help guide
providers in selecting appropriate interventions and medications for diabetic patients.
This includes lifestyle management as well as the initiation of pharmacological therapy.
The ADA standards of care provide fundamental guidance for the appropriate selection of
each medication, which medications can be used in combination, when to titrate up, add
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an addition category of medication and considerations for each. This guideline will be the
used as the foundational basis of this project.
The ADA treatment algorithm recommends metformin and comprehensive
lifestyle changes are as first steps in the treatment of Type 2 diabetes (ADA, 2019). If the
identified A1C targets are still not met after 3- months providers should consider adding a
second or third agent. If the patient has a history of atherosclerotic cardiovascular
disease, chronic kidney disease or heart failure then a Sodium Glucose Cotransporter 2
Inhibitors (SGLT-2i), Glucagon like peptide 1 receptor agonist (GLP-1 RA) should be
considered. If Atherosclerotic Cardiovascular (ASCVD) is the dominate condition, then a
GLP-1 RA should be fist consideration if not contraindicated or an SGLT2i. If chronic
kidney disease (CKD) or heart failure (HF) are dominate then an SGLT2i should be
considered if not contraindicated or an GLP-1 RA (ADA, 2019). It is important that
providers understand the maximum benefits and effects on A1C of each category of
medication. While the ADA standards of care will be the primary treatment algorithm
utilized for this project, I will briefly address the AACE treatment algorithm as well. The
AACE treatment algorithm is not much different than the ADA treatment algorithm. The
information provided in the algorithm are easy to follow guidelines which providers can
use to help obtain glycemic control when treating the Type 2 diabetic patient. It gives
easy to follow numerical A1C recommendations for the initiation of monotherapy, dual
therapy, triple therapy, and initiation of insulin (American Association of Clinical
Endocrinologists (AACE, 2015).
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There are subtle differences between the guidance provided in the ADA algorithm
and that of the AACE algorithm. The AACE recommends an A1C of 6.5% for most
patients without elevated risk of hypoglycemia. Monotherapy pharmacological
intervention is recommended for A1C of less than 7.5% (AACE, 2015). The medications
are listed in order of suggested hierarchy. This hierarchy is further recommended for dual
and triple therapy. If a patient has an A1C of 7.5% to 9.0% the AACE recommends
initiating dual or triple therapy initially. This differs from the ADA algorithm which
suggest starting dual therapy at greater than 9% (ADA, 2019) and triple therapy or
initiating insulin at 11%. The ADA table is not in order of recommended hierarchy.
Blood Glucose Levels Related to Pharmacological Management
The ADA has identified glycemic targets for patients with diabetes. Glycemic
targets should be individualized for each patient. HgA1C values should be between 6 – 8
%. The majority of nonpregnant adults should have A1C goals less than 7%. Pregnant
women should have their A1C maintained less than 6.5%. Those with multiple
comorbidities, high risk of hypoglycemia, falls, and short life expectancy can have their
A1C targets relaxed to 8% (ADA, 2019). Daily glycemic values should be kept between
70 -180 mg/dL with fasting levels kept less than 100 mg/dL for most people (ADA,
2019). Type 2 diabetes mellitus patients have a variety of pharmacological modalities
available to treat their diabetes. Each category of medication works on a different
mechanism, has contraindications, and variable costs. Each category has a maximum
expected effect on A1C values. It is essential that primary care providers understand:
what medications are available, how each works, and considerations as well as
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recommendations for use for each medication. Lifestyle management and the initiation of
oral agents are first steps in the management of diabetes.
Lifestyle Management
Lifestyle management is the first step in diabetes management. In previous years
it was recommended that lifestyle management be initiated for Type 2 diabetics at
diagnosis prior to starting medications. Current guidance is that lifestyle management
should be initiated at diagnosis along with monotherapy such as Metformin. Lifestyle
management includes adhering to a low carbohydrate diet which is appropriate diabetics,
physical activity, smoking cessation, and mental health support. For the purposes of this
project the focus for lifestyle management will be on medical nutrition therapy and
physical activity.
Medical nutrition should be implemented at diagnosis. Medication nutrition
therapy is nutrition therapy that is provided by registered dietician (Franz et al, 2014).
Medical nutrition can decrease A1C values by as much as 3%. Utilizing medical nutrition
therapy provided by a qualified nutritionist can help diabetics to achieve weight loss
goals, improve glycemic control, improve blood pressure control, improve lipid levels,
and prevent diabetic complications (Franz et al., 2014). Physical activity is another
component that can aid in improving overall health, decreasing diabetic complications
and improving A1C values. For most diabetics, it is recommended to add or increase
aerobic physical activity to 150 minutes of moderate to vigorous activity weekly. This
should be achieved over more at least 3 days a week with no more than 2 days off in
between (ADA, 2019).
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Anti-Diabetic Agents
Most medications can be used as monotherapy or adjunctive therapy. Metformin
(Glucophage) is the initial recommendation for treatment for most diabetic patients (Buse
et al., 2019). However, some patients are unable to either initiate metformin or they
cannot tolerate the side effects. In that instance other medications can be used to include,
Glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter 2
inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP-4i), thiazolidinediones
(TZDs), sulfonylureas, and insulin. If an A1C is greater than 9.0% and they have
symptoms of hyperglycemia, insulin should be initiated either as a stand-alone therapy or
with other agents (ADA, 2019). Each anti-diabetic agent works on a different component
of the body.
Metformin
Metformin is a biguanide. It is an antidiabetic oral medication used as first line
treatment in the management of Type 2 diabetes. It works by decreasing hepatic output of
glucose. Metformin can lower A1C levels by 1-2%. It is a very inexpensive medication.
Therefore, it is a great consideration for patients that have no insurance or limited
income. Metformin has been approved for use in pediatric patient older than 10 years.
Additional benefits to the use of Metformin include cholesterol lowering, no
hypoglycemia and no weight gain. It cannot be used in those with severely diminished
kidney function with a GFR less than 45 or creatinine greater than 1.4 (Avramidis et al.,
2020).
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Sulfonylureas
Sulfonylureas are another class of oral diabetic medications. These medications
stimulate the pancreas to make and release insulin. Medications in this class include
glyburide, glipizide, and glimepiride. Sulfonylureas can lower A1C levels by 1.0-2.0%.
They are a very low cost and are another good choice for those with no insurance or
limited incomes. They can cause hypoglycemia and weight gain so they should be used
with caution in the elderly and very obese (Avramidis et al., 2020).
Sodium-Glucose Cotransporter 2 Inhibitors
Sodium-glucose cotransporter 2 inhibitors (SGLT2) are a class of oral antidiabetic
medications that decrease reabsorption of glucose by the kidneys. They have an A1C
lowering capability of 0.6 – 1.5%. These medications are able to inhibit the very high capacity transporter SLGT2i which is most prevalent in the kidney. SGLT binds to
sodium and glucose and is responsible for 90% of the glucose reabsorption in the kidney.
These medications also have cardioprotective benefits and reduce risk of cardiovascular
death, heart failure and are also renal protective. The benefits include that the patient does
not experience side effects of hypoglycemia and weight gain. In fact, SGLT2i
medications often aid in weight loss. Common side effects of SGLT2i drugs include
hypotension, UTIs, mycotic infections, and ketoacidosis (Shahady & Leahy, 2010).
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are an antidiabetic injectable
therapy. They are incretin-based therapies that increase the release of insulin during
meals, slow gastric emptying, promotes early satiety and decreases glucagon release with
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food. They can lower A1C levels 0.5 – 1.6%. Most side effects are gastrointestinal and
generally subside. This category of medication should not be used in patients with a
familial history of medullary thyroid cancer. GLP-1RAs also reduce risk of
cardiovascular death, myocardial infarction, stroke, and can aid in weight loss of 1.6 –
6.0 kg (Almandoz et al., 2020).
Dipeptidyl Peptidase 4 Inhibitors
DPP-4i or dipeptidyl peptidase 4 inhibitors are another class or oral antidiabetic
medication. These medications also work in the incretin hormone. Like the GLP-1, DPP4i medications work to increase insulin secretion with food, delay gastric emptying, and
prolong action of gut hormones. They can lower A1C levels 0.6 – 0.8%. These
medications do not cause hypoglycemia or weight gain. They have been associated with
disabling joint pain. This adverse effect will generally subside upon discontinuation of
the medication.
Thiazolidinediones
Thiazolidinediones (TZDs) are a class of oral antidiabetic medication that
increase insulin sensitivity. They can lower A1C 0.5 – 1.0%. One TZD has been in the
media over the last few years with a black box warning that it caused bladder cancer.
This warning has since been redacted and replaced with a warning of increased risk for
bladder cancer. TZDs may also cause or worsen congestive heart failure as it causes the
body to retain fluid (Avramidis et al, 2020).
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Insulins
There are a variety of insulins on the market. Insulin therapy is required for Type
1 DM and LADA. Basal or long- acting insulin is meant to mimic a body’s natural
release of daily insulin. There are 2 types of basal insulin which are long-acting and
Intermediate. The difference is in the dosing, manufacturer, duration, and costs. Basal
insulins last 6-42 hours. Prandial or mealtime insulin come as rapid-acting insulting and
short-acting insulin. Like basal insulin the difference is onset, duration, costs, and
manufacturer. Onset is anywhere from 2.5 minutes to 60 minutes and duration of 3-8
hours (Avrammidis et al, 2020).
Complications
According to the CDC 1 in every 10 people have diabetes. This represents
approximately 30.3 million people (CDC, 2016). Decreased mortality combined with the
increased prevalence of diabetes means that there are more people living longer with
diabetes (Green et al., 2016). The incidence of age-related factors such as dementia
increase with the duration of diabetes. This increases the risk of associated diabetic
complications. These complications include macro-vascular complications such as
coronary artery disease (CAD), stroke and peripheral arterial disease as well as
microvascular complication such as end stage renal disease, retinopathy, and neuropathy
(Harding et al, 2019). According to Harding et al., (2019), the two most common microvascular complications associated with diabetes are retinopathy (23%) and nephropathy
(13%).
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Uncontrolled hyperglycemia is the most common cause of microvasculopathy as
well as macrovasculopathy (Chawla et al, 2016). The importance of glucose control
cannot be diminished. Early implementation of glucose control through lifestyle and
pharmacological management as well as continued maintenance greatly contribute to
minimizing diabetic complications. Poor glucose control contributes to extracellular
matrix protein synthesis, oxidative stress, and capillary membrane thickening (Chawla et
al., 2016). These are changes to microvascular and macrovascular complications of
diabetes. Identification of glycemic targets, meeting those targets and maintaining those
targets is important in both primary and secondary prevention of complications which can
lead to blindness, renal failure, myocardial infarction, stroke and increased mortality (Zhu
et al., 2017). Early management often occurs in the primary care setting. This makes this
DNP project timely and relevant. The ADA Standards of Care are the most cited and
utilized guidelines for management of diabetes. Therefore, this will be the primary
guideline utilized for this training. The ADA Standards of Care have guided the
management of diabetes in the primary care setting since 1989 (Chamberlain et al.,
2016).
Local Background and Context
In the state of Georgia, the number of elderly peoples affected by LADA and
Type 2 diabetes has grown significantly. According to the Georgia department of Public
Health, deaths related to diabetes are 8 % higher than the national average (Georgia
Department of Public Health, 2015). Georgia ranks 38th in the nation for diabetes
management. (United Health Foundation, 2019). Despite major advancement in the study
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of diabetes, there continues to be vast number of patients that are not reaching their
identified glycemic goals (ADA, 2019). The estimated per-person costs for diabetes care
and associated complication were >$10,000 over the course of eight years (Rosella et al.,
2016). Decreasing costs, decreasing negative health outcomes, and increasing positive
outcomes, as well as increasing provider knowledge and confidence are important factors
which drove the decision to conduct this DNP project.
As previously stated, this is a small privately owned primary care practice. The
owner is an internal medicine MD and as such is a major stakeholder in this project. He is
a major stakeholder because meeting HEDIS measure, getting the best outcomes for the
clinic’s patients, helping the NPs feel empowered and supported are positives outcomes
that will build and enhance this practice. The seven NPs that participated in this
education project have a variety of experience from new graduate to those with years of
experience. All patients are seen in their homes or facilities such as assisted living Many
patients are home bound, therefore have a difficult time seeing specialists due to physical
issues and the challenges of medical transport. Cost often prohibits special transportation
to a clinic appointment and there is not access to an endocrinologist. The NPs, as
providers in this practice, often manage all aspects of their patients’ care. These NPs are
bridging a gap by providing care to this underserved population. They help to decrease
cost of care by providing frequent visits, improving access to care, and providing a quick
response to need (Jones et al, 2017).
The majority of patients treated by this project site are over 60 years of age. Over
60% of diabetes related healthcare costs are spent on those over the age of 65 (Rosella et
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al, 2016). During internal audits, the Administrator of the practice noticed that many
patients are not meeting their A1C goals. NPs also self-identified limited knowledge
regarding some categories of diabetes medications and therefore do not commonly
prescribe them. This staff education may help to improve NP ability to create
individualized EBP care plans utilizing a combination of pharmacological approaches.
Safe and appropriate treatment aimed at adequate glycemic control in diabetes is essential
in decreasing both individual and societal disease burden (Leon et al., 2015).
Role of the DNP Student
I am a master’s prepared registered advanced practice registered nurse with 10
years of experience. I currently work as a NP and certified diabetic educator in an
outpatient endocrinology office in a hospital setting. Many primary care physicians, NPs
and physician assistants refer their diabetic patients to us for consultation and
management. Through these consults it is evident the lack of knowledge and confidence
in managing these patients beyond one or two medications. The practice in which this
project will be completed is a former employer. During my tenure there I saw firsthand
the complexity of the diabetic patients of the practice as well the limited knowledge,
confidence, and experience of the providers. The role of a doctoral prepared nurse is to
improve clinical outcomes for patients through education and example in clinical
leadership (Richardson et al., 2014).
I served as the leader of this DNP capstone project. This project was created
utilizing the treatment guidelines from the ADA and AACE. No personal opinions or
conjecture were added. I also served as facilitator for the expert panel discussion.
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Steps in the Development of a Staff Education Project
The diabetes staff education project began with a discussion with the director for
advance practice providers and the medical director. A current need was identified related
to NP education on the medical management of diabetic patients. The medical director
determined that this education program would be a positive tool to help strengthen
diabetes management for the NPs within the practice. The project was implemented
during plan is to implement a regularly schedule staff meeting. This staff education
project followed Walden University’s DNP Manual for Staff Education. I reviewed the
ADA standards of care, materials from The Association of Diabetes Care & Education
Specialists (ADCES), and the AACE guidelines to prepare the presentation. I obtained
Walden University Institutional Review Board (IRB) number 11-16-20-0676748
approval prior to starting the project.
Role of the Project Team
Expert Panel
Content for the project presentation was reviewed by an expert panel made up of
two endocrinologists and one registered nurse educator who is also a certified diabetes
care and education specialist (CBDCES). The panel of experts were presented the powerpoint content via email and then provided recommendations for feedback.
Endocrinologist 1 signed off on the presentation stating he felt it was thorough and
appropriate for the clinical setting and audience identified. Endocrinologist 2 suggested
made the following suggestions: “Add that Type 2 diabetes mellitus is usually overweight
while LADA and T1DM typically have normal BMI, Different forms of GLP1 weekly
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and the daily. Add Rybelsus as we want advocate that GLP1 and SGLT2i provide weight
loss and cardiovascular benefit so these medications should be on top of list after
metformin. Add a slide on lifestyle change: exercise 150 minutes per week, weight loss
of 5% can have significant impact and limit carbohydrate intake to 60 grams per meal.”
The Registered nurse educator echoed Endocrinologist 2 input.
I then incorporated the changes into the presentation. The team assembled in our
clinic meeting room for a review and final discussion of the presentation. The panel
agreed the presentation was appropriate and ready for dissemination. As leader of this
DNP project I assumed responsibility for the presentation and sent a finalized copy to the
medical director of the project site and requested for any input. The only concerns he
voiced were regarding time management. Originally, a time frame of 45 minutes was
allotted to complete the presentation. However, due to clinic time constraints he
requested the information be presented within a 30- minute time slot. I agreed to the 30minute period and moved forward with scheduling the presentation with clinic
administration.
Summary
In Section 2 of the DNP capstone project I discussed the CCM which served as
the framework to support this project. The need for the project and relevance to nursing
practice, local context, and the role of the DNP student are explained. In section 3 I will
discuss sources of evidence, collecting and analyzing sources of evidence, and project
results.
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Section 3: Collection and Analysis of Evidence
Section 3 includes the sources of evidence, project design, data collection, and
survey tool for evaluation of the project. Evidence-based education on pharmacological
management of the Type 2 diabetic and LADA patient can improve provider confidence,
knowledge, ability and improve patient outcomes. Several NPs in the practice have
voiced their lack of confidence in pharmacologic management of these diabetic patients.
The practice management and physician collaborators are providing the support for the
project and recognize the need to educate the NPs to provide evidence-based patient care
and medical management. Section 3 will include discussions of the sources of evidence,
project design, and the analysis and synthesis of project results.
Practice-Focused Question
Diabetes is a global health issue and a local practice problem. This DNP project
was designed to address the local practice problem within a small primary care practice in
southeastern Georgia. The practice-focused question that guided this project was: Will an
educational program presented to primary care NPs on the pharmacological management
of diabetic patients increase the practitioners’ perceived confidence and knowledge in
treating and managing diabetic patients? The purpose of this project was to develop staff
education based on ADA and AACE standards of care, deliver the education to primary
care NPs, and evaluate their learning and confidence levels. The evaluation of learning
was completed by providing participants with a Likert-style survey prior to the education
intervention. The same survey was again given after the educational intervention. The
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presurvey and postsurvey were collected and the differences between the two
assessments were recorded.
The practice problem is related to the prevalence of diabetes in the state of
Georgia, burden of cost of care, increase in mortality, and the need for primary care NP
education to manage the condition. The practice where this project was implemented has
a high percentage of diabetic patients; approximately one of every four patients are living
with diabetes. I worked for this practice for 3 years and helped begin implementation of a
diabetes management program. In my current role working as an endocrinology NP with
a focus on diabetes, I have been able to observe the knowledge deficit with management
of diabetic patients in the primary care setting. The NPs at this practice have varying
degrees of competency regarding pharmacological management of these patients. This
DNP project was centered around educating NPs on the ADA and AACE guidelines for
pharmacological management of Type 2 and LADA diabetic patients.
Sources of Evidence
Sources of evidence for this project included an exhaustive review of the literature
for appropriate and reliable information on diabetes management. I searched databases
such as MEDLINE, CINAHL, Pub Med, CINAHL full text, Ovid Nursing Journals,
National Institutes of Health (NIH), and EBSCO host. Other sources of evidence included
guidelines from the ADA and the AACE. Key search terms used were diabetes, Type 2,
LADA, antidiabetic, medications, SGLT2i, GLP-1 RA, sulfonylurea, metformin,
treatment, DPP4i, insulin, basal, prandial, bolus, outpatient, primary care, nurse
practitioner, hyperglycemia, and glycemic control. Journal articles must have been

28
published within the last 6 years, evidence-based, peer-reviewed, and published in
English. Guidelines were from the ADA and AACE. Input and opinions from an expert
panel also served as a source of evidence. Evidence collected was used to create
educational intervention appropriate for NPs in a primary care clinical setting. The
collection and analysis of this evidence provides an appropriate method to address the
practice-focused question.
Evidence Generated for the Doctoral Project
A data source for this project was evidence obtained during an exhaustive search
of the literature regarding management of diabetes in primary care. Other sources of
evidence included input and opinions from the expert panel as identified in the previous
section as well as data from the ADA and AACE. Due to time constraints identified by
the project site medical director, the education program had to be completed in 30
minutes. The program was delivered during an already scheduled staff meeting and
completed on their online meeting platform. I created a 13-question Likert-style survey
with ratings from 0–5. The surveys asked participants to rate their level of confidence in
managing each category of medication reviewed in the presentation.
The preassessment and postassessment surveys were separated by the staff
education intervention on the pharmacological management of diabetics. As leader, I
conducted the staff education presentation that incorporated the most current evidencebased practice guidelines based on the ADA and AACE guidelines. I provided
information on the most common types of diabetes seen in primary care along with
treatment algorithms from the ADA and AACE. Common medications were discussed
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including mechanism of actions, maximum benefit, dosage recommendations,
contraindications, and most common side effects. I encouraged staff participation by
asking questions pertaining to medications and responding to questions and concerns
related to the NPs’ specific patient population.
Six NPs, two medical doctors and two administrative staff of the practice
participated in the project. The preassessment survey was emailed to the director of
advanced practice providers the day previous. Only the participating NPs were provided
with and asked to complete the survey. She assigned each NP that participated a number
from 1-7. Those results were collected by her prior to the staff education intervention and
emailed back to me with the words provider number and a number from 1-8 placed in the
upper right corner. I received seven preassessment surveys prior to the intervention. The
staff education was completed by sharing the power point along with an oral presentation
of the information included in the slides. Following the presentation, the staff were asked
to complete their postassessment surveys and return them. Again, the director collected
the post assessment surveys and returned them to me via email. I received six
postassessment surveys. Since each of the surveys were randomized, I was uncertain
which provider did not return their survey.
The providers of the project site were informed that by completing and returning
the pre and post assessment surveys that participation was regarded as consent to
participate in the project. They were informed that could change their mind about
participation at any time by not completing the assessments. The staff were informed of
how their surveys would be sent to them and how they would be collected. They were
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provided with the opportunity to voice any concerns regarding the project and collection
of survey data. They were assured that identifies would remain anonymous, private, and
confidential. There were no further ethical dilemmas anticipated.
Protections
The Site Agreement Form Anonymous Questionnaire was signed by the
Administrator of the practice and submitted with Form A to the Walden IRB for
approval. The Walden University Institutional Review Board (IRB) approved the project
and the staff education was completed under IRB number 11-16-20-0676748. The
diabetes staff education project began with a discussion with the medical director
regarding the need for provider education on diabetic patient management. The
educational program focused on pharmacologic management for this patient population.
The aim of the project was to meet an educational need for providers to feel more
knowledgeable in the medical management of diabetic patients. The medical director is
very supportive of the project after determining that this education program would be a
positive tool to help strengthen diabetes management for the NPs within the practice. The
project was implemented virtually during a regularly schedule staff meeting. This was at
the request of the medical director and follows the COVID-19 guidelines for the clinic.
Analysis and Synthesis
All providers at the clinic were invited to participate in the educational program
(Appendix A). Participants were asked to complete a survey to assess pharmacological
knowledge prior to the education program. Upon completion of the education
intervention, the same anonymous survey was provided to the participants to evaluate the
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perceived confidence and knowledge on pharmacological management for diabetic
patients. The pre/post survey consist of 13 questions. Each question was answered using
a 5-point Likert scale (Appendix B). The Likert scale ranges from strongly disagree to
strongly agree. All survey results are anonymous to me and will remain confidential. The
clinical advanced practice director disseminated and collected the surveys, each of which
were given random numbers and then she returned all the collected surveys to me in one
email. The project site is located over two hours away from my location. Due to Covid19 concerns and the ability to meet in person, this was most proficient way to allow for
anonymity to the writer given that this will all be completed using virtual platforms and
email technology I completed a quantitative review of the survey results. The review
includes the number of study participants and scores from pre and post survey
assessment. The collected data was analyzed by pairing results for each provider and
compiling those results in table to compare clinician perceived confidence in their
knowledge and ability to manage their patients on the various categories of medications.
Summary
In this section I focused on the collection and analysis of the evidence, project
design, and the local practice gap within a small primary care practice in southeastern
Georgia. I also addressed the practice-focused question that guided this DNP project. The
potential benefits of this project were to increase NP knowledge and confidence in
pharmacological management of their diabetic patients. Section 4 includes the evaluation
and findings of the project.
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Section 4: Findings and Recommendations
Diabetes is currently one of the most common chronic diseases treated in primary
care. Understanding evidence-based pharmacological management of these patients is
essential to preventing associated complications, decreasing hospitalizations, helping
patients achieve better quality of life, and ensuring practitioners meet HEDIS measures
that directly affect compensation. During chart reviews, the administrator of the project
site noted continued increases in the A1C of their diabetic patients as well as increased
hospitalizations with diabetic complications. Many of the wound care patients the project
site treats are diabetic, and poor glycemic control greatly contributes to slow wound
healing. One possible contributing factor to these outcomes identified was limited
provider knowledge on pharmacological management of diabetic patients. This identified
gap in practice was addressed through this staff education project.
The practice-focused question that guided this project was: Will an educational
program presented to primary care NPs on the pharmacological management of diabetic
patients increase the practitioner’s perceived confidence and knowledge in treating and
managing diabetic patients? The purpose of this project was to develop staff education
based on ADA and AACE standards of care, deliver the education to primary care NPs,
and evaluate their learning and confidence levels. The sources of evidence used to
complete this project included an extensive of clinical databases such as MEDLINE,
CINAHL, Pub Med, CINAHL full text, Ovid Nursing Journals, National Institutes of
Health (NIH), and EBSCO host. Other sources of evidence included guidelines from the
ADA and the AACE as well as expert opinion and input from the panel of experts. In
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Section 4, I discuss project findings, recommendation, strengths, and limitations of the
project.
Findings
This staff educational program (Appendix A) was successful in attaining the goal
of increasing NP confidence in the pharmacological management of diabetic patients. A
preassessment survey was provided to the providers of the project site. There were seven
NPs and two physicians who participated in the program. The preassessment surveys
were collected by the director prior to the presentation. The education program consisted
of a PowerPoint presentation and an open question-and-answer session. Instructions were
given to the participants regarding the completion of the postassessment surveys. Again,
participants were reassured that participation would be completely anonymous and each
survey would be returned and reported with a randomly assigned number from 1–9. The
education program session lasted approximately 35 minutes. The postassessment surveys
were collected by the director and returned to me via email. Each set of preassessment
and postassessment surveys were paired with an assigned provider number. The results of
each were compiled in a table and the results reviewed and compared to answer the
practice-focused question.
Preassessment
Table 1 presents a summary of the data from the preassessment survey (see
Appendix B). At the beginning of the presentation, I explained to the providers that the
purpose of the presentation was to increase provider knowledge and confidence in the
pharmacological management of their diabetic patients. Appendix B was used as a
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preintervention self-evaluation of provider knowledge and confidence in the
pharmacological management of their diabetic patients. Seven (n = 100%) NPs
completed the preassessment evaluation. The MDs reported that they would participate in
the presentation but not in the survey. The self-evaluation was presented in a written
Likert-scale format. The options were numbered 1–5 for very comfortable, somewhat
comfortable, neutral, somewhat uncomfortable, and very uncomfortable.
The self-assessment questionnaire consists of the following 13 questions: 1)
providers were asked what their general levels of comfort was in adjusting basal insulin.;
2) providers were asked what their general level of comfort was in adjusting prandial
insulin; 3) providers were asked what their general level of comfort was in adjusting premixed insulin; 4) providers were asked their level of comfort with ADA/AACE treatment
recommendations; 5) providers were asked their level of comfort with which oral and
injectable therapies could be combined; 6) providers were asked their level of comfort in
their knowledge of the maximum effects each class of medication has on A1C values; 7)
providers were asked their level of comfort with the metformin; 8) providers were asked
their level of comfort with sulfonylureas; 9) providers were asked their level of comfort
with DPP4i medications; 10) providers were asked their level of comfort with SGLT2i
medications; 11) providers were asked their level of comfort with GLP1RA medications;
12) providers were asked their level of comfort with thiazoldinediones; 13)providers
were asked their level of comfort with selecting medications that are cardio and renal
protective.
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Question 1 Four NPs (57%) selected 3 for both Questions 1 and 2, indicating that
they felt neutral about their knowledge and confidence in adjusting basal and prandial
insulin. Two NPs (29%) selected 4 for both Questions 1 and 2, indicating they felt
somewhat comfortable about their knowledge and confidence in adjusting basal and
prandial insulin. One NP (14%) selected 5 for both Questions 1 and 2, indicating they felt
very comfortable about their knowledge and confidence in adjusting basal and prandial
insulin.
The data showed that two NPs (29%) stated they felt very comfortable with
recommending lifestyle management, Question 3, to their patients. Three NPs (43%)
selected 4, and two NPs (29%) selected 3 for their response. Three NPs (43%) selected 4
for both Questions 4 and 5, and four NPs (57%) selected 2, reporting they felt very
uncomfortable with ADA/AACE treatment recommendations and combining oral and
injectable medications. Two NPs (14%) selected 3 for Question 6, and five NPs (71%)
selected 2. Question 7 seemed to be the area in which most of the NPs felt most
comfortable. Six NPs (86%) selected 1, and one NP (14%) selected 2. Three NPs selected
4 (57%) for Question 8, two NPs (29%) selected 3, and two NPs (29%) selected 2. Two
NPs (29%) selected 4 for Question 9, three NPs (43%) selected 3, and two NPs (29%)
selected 2. One NP selected 4 for Question 10, three NPs (43%) selected 3, two NPs
(29%) selected 2, and one NP (14%) selected 1. Three NPs (43%) selected 3 for Question
11. Two NPs (29%) selected 3, four NPs (57%) selected 2, and one NP (14%) selected 1
for Question 12. Two NPs (29%) selected 4 for Question 13. Three NPs (43%) selected 3,
and two NPs (29%) selected number 2 for Question 13.

36
Table 1
Nurse Practitioner Preassessment Results (N = 7)
5 (VC)
n (%)
1 (14)
1 (14)
2 (29(

4 (SC)
n (%)
2 (29
2 (29)
3 (43)
3 (43)
3 (43)

3 (N)
n (%)
4 (57)
4 (57)
2 (29)
4 (57)

2 (SU)
n (%)

1 (VU)
n (%)

Q1
Q2
Q3
Q4
Q5
4 (57)
Q6
2 (29)
5 (71)
Q7
6 (86)
1 (14)
Q8
3 (43)
2 (29)
2 (29)
Q9
2 (29)
3 (43)
2 (29)
Q10
1 (14)
3 (43)
2 (29)
1 (14)
Q11
3 (43)
3 (43)
1 (14)
Q12
2 (29)
4 (57)
1 (14)
Q13
2 (29)
3 (43)
2 (29)
Note. VC = Very comfortable, SC = Somewhat comfortable, N = Neutral, SU =
Somewhat uncomfortable, VU = Very uncomfortable.

Postassessment
After the power-point presentation the providers were given time for a question
and answer session. Once the providers exhausted their questions, they were invited to
again complete Appendix B as a post-education self-assessment. Table 2 represents the
results of the post-education self-assessment survey. Only six NPs returned the posteducation self-assessment survey to the director. The assessments were paired with
anonymous numbers 1-7. Participant 5 did not return their post-education selfassessment. Therefore, the post-education survey is N=6.
The data showed improvement in all areas of the survey. Four NPs (67%) selected
number 5 for question 1 and two NPs (33%) selected number 4. The data showed that
three NPs (50%) selected number 5 for question 2, 2 NPs (33%) selected number 4 and 1
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NP (17%) selected number 3. All six NPs (100%) selected number 5 for questions 3 and
4. Five NPs (83%%) selected number 5 for question 5 and one NP (17%) selected
number 4. The data shows that all six NPs (100%) selected number 5 for questions 6, 7,
8, 9, 10, 11 and 12. Five NPs (83%) selected number 5 for question 13 and one NP (17%)
selected number 4.
Table 2
Nurse Practitioner Postassessment Results (N = 6)
5 (VC)
4 (SC)
3 (N)
2 (SU)
1 (VU)
n (%)
n (%)
n (%)
n (%)
n (%)
Q1
4 (67)
2 (33)
Q2
3 (50)
2 (33)
1 (17)
Q3
6 (100)
Q4
6 (100)
Q5
5 (83)
1 (17)
Q6
6 (100)
Q7
6 (100)
Q8
6 (100)
Q9
6 (100)
Q10
6 (100)
Q11
6 (100)
Q12
6 (100)
Q13
5 (83)
1 (17)
Note. VC = Very comfortable, SU = Somewhat comfortable, N = Neutral, SC =
Somewhat uncomfortable, VU = Very uncomfortable.

This staff education project demonstrated that providing NPs in a small primary
care office with education on the pharmacological management of the diabetic patients
increases their confidence in their knowledge and ability to manage those patients. The
results of this study align with the goals of the CCM which seeks to create systems to
enhance diabetes management in the primary care setting by bridging the gap between
evidence-based practice and negative patient outcomes (Bongaerts et al., 2017). This
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project met the purpose which was to develop staff education based on ADA and AACE
standards of care, deliver the education to primary care NPs, and evaluate their learning
and confidence levels.
The primary goal is for NPs to utilize this knowledge and confidence to partner
with their patients to design individualized treatment plans. This will help to improve
patients’ quality of life, help the project site to meet HEDIS measures, and decrease the
socio-economic cost burden associated with poor diabetic outcomes. Knowledge and
confidence will allow each provider to address patient cultural beliefs, financial needs,
comorbidities and emotional concerns when generating an individualized treatment plan
(Germossa et al., 2018).
Recommendations
Primary care knowledge and confidence in selecting appropriate pharmacological
agents for their diabetic patients is an important component is diabetic management.
Gerald et al., (2010) proposes that structured nursing education should be conducted
through continuous training programs which enhance proficiency and help nurses to keep
up to date with current evidence-based practices in the management of diabetes. I
recommend that a recurring education program on diabetes management which includes
scenarios and perhaps real time case reviews be implemented at the project site. In
addition, a regularly scheduled review of HEDIS measures and goals may prove to be
beneficial. This will allow the project site providers to better understand how effective
the interventions they are selecting for their diabetic patients have been. Another
suggestion for the project site is to provide patient encounter visit that focus solely on

39
diabetic management and care. This will allow the providers to spend quality time not
only reviewing labs and medications but to discuss other lifestyle modifications and
provide intensive diabetic education to their homebound patients.
Strengths and Limitations of the Project
A major strength to this DNP project was that the medical director and
administrative director were supportive of the project. The providers were receptive to
the information and felt the information was useful and applicable to their practice. The
presentation was easy to follow, evidence-based and up-to-date. A major limitation of
this project was the limited sample size. Only 7 NPs participated in the education and
only 6 completed both pre and post self-evaluation assessments. The project was
completed at a single site. The larger sample size or multiple sites may yield different
results. Therefore, it is impossible to generalize the findings. Another limitation was the
allotted time. I was given 30 minutes to complete the project. While I was able to
complete within the timeframe more time would have allowed for the providers to truly
process the information and allotted for a more robust questions and answer session. The
way the surveys were dissemination and collected could be considered a limitation.
Section 5: Dissemination Plan
Section 5 is the final phase of the DNP project. The focus of this section is the
dissemination of findings. In this section, I include self-reflection and analysis as well as
a review of the dissemination plan for the results of the project. The aim of the project
was to generalize the education for use in outpatient clinics, hospitals, and other
professional in-service training programs. This diabetes education program demonstrates
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potential to empower primary care NPs and other providers to create pharmacological
care plans individualized to each patient. This improves patient outcomes and enhances
quality of life.
Dissemination
This project was created and delivered using evidence-based guidelines from the
ADA and AACE. I provided the project site with an emailed copy of the PowerPoint
presentation used in the staff education program. Providing the materials helps to
promote continuing education by allowing them ease of access to the material. The
project site can then use the presentation to conduct refresher training for current staff
and initial training for new hires. It will be the responsibility of the directors and each
provider to remain up to date with current literature and changes in treatment standards.
The project site can also use the information to create handouts for their providers to use
as a quick resource. The preassessment and postassessment surveys indicated that the
NPs who participated in the education program experienced an increase in knowledge on
the pharmacological management of diabetic patients. The participating NPs also
experienced an increase in confidence levels to manage and select appropriate medication
for patients. All participants were asked to provide feedback on the quality of the
presentation.
Analysis of Self
My passion for diabetes began while working as a field NP with this project site a
few years ago. It was during my tenure at this practice that I began to understand how
important it was to understand every component of diabetes, especially how each
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medication could be beneficial to my patients. Many of the patients are on fixed or
limited incomes and out-of-pocket costs are a major consideration. It was disheartening
to see patients return from the hospital with care plans I knew they would never be able
to follow. This inability to adhere to a care plan would often lead to rehospitalizations.
These experiences were the driving force behind my passion for helping those living with
diabetes experience a good quality of life. I have worked diligently to understand the
pharmacodynamics of medications and learned the out-of-pocket costs associated with
various insurances. Educating primary care staff and their patients to help improve
patient outcomes is my main goal.
As a scholar, I use evidence-based practice to create effective educational
interventions for providers. The goal is for those providers to take what they have learned
and use the knowledge to treat and educate their patients and other healthcare staff.
Healthcare is an ever-changing landscape. It is essential that providers seek educational
opportunities to resolve knowledge gaps. The purpose of this project was to develop staff
education based on ADA and AACE standards of care, deliver the education to primary
care NPs, and evaluate their learning and confidence levels. I met this purpose and
achieved my scholarly goals for this DNP project.
As the project leader I was able to effectively lead a team of subject matter
experts. During my time as a DNP student and throughout this project I have grown
greatly in patience and communication. COVID-19 created some interesting hurdles.
Through effective communication and collaboration with the project site leadership I was
able to complete the project and achieve my purpose. Completing this staff education
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project served as a reminder of the importance of remaining up to date on the literature
and research regarding diabetes. Teaching other providers is very rewarding. I intend to
put the knowledge and skills developed during the DNP experience to good use. It has
enforced my faith in my own leadership abilities which I intend to use to teach and train
current and future generations of NPs.
Summary
This DNP project served to educate NPs about the pharmacological management
of diabetes patients. Utilizing the ADA and AACE guidelines demonstrated to those that
participated how they can use EBP in their own practice when treating their diabetic
patients. As society continues to navigate a new normal and learn how to deliver inservices, hold meetings, and continue social distancing, the use of online media and
power-point presentations are valuable tools. Based on the findings of this project, the
creation of a routine staff education component would be beneficial to the project site.
The findings of the pre and post assessment survey show that NPs did indeed increase
their knowledge and confidence in managing their diabetic patients.
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Appendix A: Diabetes Management PowerPoint Presentation
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Appendix B: Pre/Post Assessment
I. Self-Assessment: Insulin Therapies
Directions: The following statements assess your comfort with managing insulin therapy
in the home. Please rate yourself on a scale from 1-5 with 0 = VERY
UNCOMFORTABLE to 5 = VERY COMFORTABLE. Circle the number that BEST
describes you. (Comfort is defined as a feeling of ease in performing the following
skills).
1. General level of comfort in adjusting subcutaneous basal insulin
0........1........2........3........4........5
2. General level of comfort in adjusting subcutaneous prandial insulin
0........1.........2........3........4.........5
3. General level of comfort in adjusting pre-mixed insulin therapy
II. Self-Assessment oral and injectable therapies
Directions: The next series of statements assess your comfort with managing oral and
injectable therapies. Please rate yourself on a scale from 1-5 with 0=VERY
UNFAMILIAR to 5=VERY FAMILIAR. Comfort is defined as a feeling of ease in
performing the following skills).
4. General level of comfort with ADA/AACE treatment recommendations
0........1........2........3........4........5
5. General level of comfort with what oral and injectable medications can be
combined
0........1........2........3........4........5
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6. General level of comfort with maximum effects each class of medication has on
A1C
0........1........2........3........4.........5
7. General level of comfort with Metformin
0........1........2........3.........4.........5
8. General level of comfort Sulfonylureas
0........1........2........3........4........5
9. General level of comfort with Dipeptidyl peptidase 4 (DPP-4)
0........1........2........3........4........5
10. General level of comfort with Sodium Glucose Cotransporters 2 Inhibitors
0........1........2........3........4........5
11. General level of comfort with Glucagon Like Peptidyl 1 Receptor Agonists
0........1........2........3........4........5
12. General level of comfort Thiazolidinediones
0........1........2........3........4........5
13. General level of comfort with selecting medications that are cardio and renal
protective (GLP-1RA and SGLT2i)
0........1........2........3........4........5

